SCHEMBL3475191

SCHEMBL3475191

Cc1nc2ccc(-c3cccc(C(F)(F)F)c3)cc2n(C)c1=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TGFBR1 P36897 1/20 0.48
GRIN1 Q05586 11/20 0.47
GRIN2B Q13224 11/20 0.47
KDM4E B2RXH2 3/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
ALDH1A1 P00352 2/20 0.47
GLA P06280 1/20 0.47
HPGD P15428 1/20 0.47
BRD9 Q9H8M2 1/20 0.46
GSR P00390 1/20 0.46
CYP1A2 P05177 2/20 0.46
CYP2C9 P11712 2/20 0.46
CYP2C19 P33261 2/20 0.46
HTT P42858 2/20 0.46
MEN1 O00255 1/20 0.46
CYP2D6 P10635 1/20 0.46
KMT2A Q03164 1/20 0.46
ABL1 P00519 1/20 0.44
LCK P06239 1/20 0.44
KIT P10721 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3472610 0.88 KDM4E (0.50) KDM4ESMN1; SMN2ALDH1A1GLAHPGD
SCHEMBL28285676 0.85 KDM4E (0.55) KDM4ESMN1; SMN2ALDH1A1GLAHPGD
SCHEMBL13366929 0.83 KDM4E (0.53) TGFBR1KDM4ESMN1; SMN2ALDH1A1GLA
SCHEMBL3474781 0.82 PDE10A (0.44) GRIN1GRIN2BKDM4ESMN1; SMN2ALDH1A1
SCHEMBL3376506 0.81 SCD (0.51) GRIN1GRIN2BKDM4ESMN1; SMN2ALDH1A1
SCHEMBL15147603 0.80 KDM4E (0.58) KDM4ESMN1; SMN2ALDH1A1GLAHPGD
SCHEMBL3473860 0.78 ALDH1A1 (0.53) GRIN1GRIN2BKDM4ESMN1; SMN2ALDH1A1
SCHEMBL3473462 0.78 SMN1; SMN2 (0.47) KDM4ESMN1; SMN2ALDH1A1GLAHPGD
SCHEMBL3433378 0.78 TGFBR1 (0.51) TGFBR1GRIN1GRIN2BKDM4ESMN1; SMN2
SCHEMBL3474070 0.76 TGFBR1 (0.49) TGFBR1GRIN1GRIN2BKDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8912190-B2 Substituted heterocyclic compounds GILEAD SCIENCES, INC. (US) 2014-12-16 US claimed
US-20130197001-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS GILEAD SCIENCES, INC. (US) 2013-08-01 US claimed
US-20100113461-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS GILEAD PALO ALTO, INC. (US) 2010-05-06 US claimed
US-8912190-B2 Substituted heterocyclic compounds GILEAD SCIENCES, INC. (US) 2014-12-16 US disclosed
US-8912190-B2 Substituted heterocyclic compounds GILEAD SCIENCES, INC. (US) 2014-12-16 US disclosed
US-20130197001-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS GILEAD SCIENCES, INC. (US) 2013-08-01 US disclosed
US-20130197001-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS GILEAD SCIENCES, INC. (US) 2013-08-01 US disclosed
US-20100113461-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS GILEAD PALO ALTO, INC. (US) 2010-05-06 US disclosed
US-20100113461-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS GILEAD PALO ALTO, INC. (US) 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113461-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS KCNH1, KCNJ2, KCNH2 TGFBR1 1618/4885GRIN1 1435/4885GRIN2B 2067/4885
US-20130197001-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS KCNH1, KCNJ2, KCNH2 TGFBR1 1618/4885GRIN1 1435/4885GRIN2B 2067/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.